A spectrum of cutaneous toxicities from erlotinib may be a robust clinical marker for non-small-cell lung therapy: a case report and literature review

Some literature suggests that an EGFR inhibition-induced rash can be used as a clinical marker, but few studies report the correlation between a spectrum of cutaneous toxicities from EGFR inhibition and drug efficacy. We report about a woman with a stage IV lung adenocarcinoma using erlotinib monoth...

Descripción completa

Detalles Bibliográficos
Autores principales: Jin, Feng, Zhu, Hui, Kong, Li, Yu, Jinming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4410898/
https://www.ncbi.nlm.nih.gov/pubmed/25960666
http://dx.doi.org/10.2147/OTT.S83888

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4410898/
https://www.ncbi.nlm.nih.gov/pubmed/25960666
http://dx.doi.org/10.2147/OTT.S83888

Ejemplares similares